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The potential of MRI to
estimate radiation-absorbed
dose distributions of
holmium-166 loaded poly
(L-lactic) microsphere
(166Ho-PLLA-MS) was
investigated using the dose
point-kernel convolution
method. Quantitative MRI
was demonstrated to provide
accurate three-dimensional
166Ho-PLLA-MS bio-
distributions and by direct
proportion 166Ho activity
distributions, which facili-
tated localized intrahepatic
radiation-absorbed dose esti-
mation by convolution with
a 166Ho dose point-kernel.
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Open access undPurpose: To investigate the potential of magnetic resonance imaging (MRI) for accurate assess-
ment of the three-dimensional 166Ho activity distribution to estimate radiation-absorbed dose
distributions in 166Ho-loaded poly (L-lactic acid) microsphere (166Ho-PLLA-MS) liver radioem-
bolization.
Methods and Materials: MRI, computed tomography (CT), and single photon emission CT
(SPECT) experiments were conducted on an anthropomorphic gel phantom with tumor-
simulating gel samples and on an excised human tumor-bearing liver, both containing known
amounts of 166Ho-PLLA-MS. Three-dimensional radiation-absorbed dose distributions were
estimated at the voxel level by convolving the 166Ho activity distribution, derived from quanti-
tative MRI data, with a 166Ho dose point-kernel generated by MCNP (Monte Carlo N-Particle
transport code) and from Medical Internal Radiation Dose Pamphlet 17. MRI-based radiation-
absorbed dose distributions were qualitatively compared with CT and autoradiography images
and quantitatively compared with SPECT-based dose distributions. Both MRI- and SPECT-
based activity estimations were validated against dose calibrator measurements.
Results: Evaluation on an anthropomorphic phantom showed that MRI enables accurate
assessment of local 166Ho-PLLA-MS mass and activity distributions, as supported by
a regression coefficient of 1.05 and a correlation coefficient of 0.99, relating local MRI-
based mass and activity calculations to reference values obtained with a dose calibrator.
Estimated MRI-based radiation-absorbed dose distributions of 166Ho-PLLA-MS in an
ex vivo human liver visually showed high correspondence to SPECT-based radiation-
absorbed dose distributions. Quantitative analysis revealed that the differences in local
and total amounts of 166Ho-PLLA-MS estimated by MRI, SPECT, and the dose calibrator
were within 10%. Excellent agreement was observed between MRI- and SPECT-based
doseevolume histograms.
Conclusions: Quantitative MRI was demonstrated to provide accurate three-dimensional
166Ho-PLLA-MS activity distributions, enabling localized intrahepatic radiation-absorbed., Room Q S.459, PO Box
. (þ31) 88-75-53172; Fax:
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obtained with a dose
calibrator.dose estimation by convolution with a 166Ho dose point-kernel for liver radioembolization
treatment optimization and evaluation.
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During the past decade, over 30,000 patients suffering from unre-
sectable primary or metastatic liver tumors were treated by hepatic
arterial radioembolization (RE) with high-energy b-radia-
tioneemitting microspheres (1, 2). Apart from the amount of
radioactivity that is administered, the efficacy of this type of
internal radiation therapy is postulated to depend on the intra-
hepatic dose distribution (2e4). By administering the microspheres
intra-arterially, the predominance of the arterial supply to liver
tumors is exploited, generally resulting in a high tumor-to-normal
tissue ratio (5). However, the large variation in vascularity of tumor
and liver observed between patients necessitates extensive treat-
ment planning to ensure a favorable dose distribution in each
individual patient (6). The currently used radioactive microspheres
for RE contain the b-emitting radionuclide 90Y, which does not
facilitate quantitative biodistribution assessment, despite develop-
ments involving Bremsstrahlung imaging (7) and more recently
positron emission tomography (8). Therefore, in clinical practice,
99mTc macroaggregated albumin (MAA) is used as a surrogate,
aiming to estimate the lung-shunt fraction, to detect extrahepatic
deposition, and to assess intrahepatic dose distributions using
planar scintigraphy and single photon emission computed tomo-
graphy (SPECT). The differences in size distribution (10e90 mm),
number of particles, shape, density, and consequently hemody-
namic properties of 99mTc-MAA particles, along with the sizeable
amount (up to 10%) that is well below 30 mm, are hypothesized to
cause the discrepancies observed between the biodistribution of
99mTc-MAA particles and the 90Y microspheres (7).
166Ho-loaded poly (L-lactic acid) microspheres (166Ho-PLLA-
MS) constitute an alternative RE device, which currently is the
subject of a Phase I clinical trial (9). 166Ho-PLLA-MS possesses
attractive radiation characteristics (Ebmax Z 1.77 MeV [48.7%]
and 1.85 MeV [50.5%], Eg Z 81 keV [6.7%], t1/2 Z 26.8 h) for
both therapy and quantitative SPECT imaging (6, 10e12). Inter-
estingly, holmium is highly paramagnetic, which is independent of
radioactivity, making both neutron-activated and nonactivated Ho-
PLLA-MS an ideal MR contrast agent (12, 13). These properties
yield a single microparticle suitable for RE with the potential of
in vivo quantitative biodistribution assessment. Additionally, MRI-
guided catheterization and administration of Ho-PLLA-MS was
shown to allow real-time in vivo monitoring of microsphere
delivery to the tumor site (13, 14). More recently, we reported the
development of a fast quantitative MR imaging technique that
enables accurate quantification of the distribution of Ho-PLLA-
MS at the level of a voxel (15).
The purpose of this study was to test the hypothesis that MRI
can be used to accurately assess the 3D 166Ho-PLLA-MS activity
distribution to enable radiation-absorbed dose estimation for
treatment planning optimization and follow-up of transcatheter
liver RE. To this end, MRI experiments were conducted on an
anthropomorphic gel phantom and on an ex vivo human liver with
tumors after postexcision arterial RE with 166Ho-PLLA-MS. Bythe use of a 3D 166Ho dose-point kernel, and after transformation
of the quantitative MRI-based 166Ho-PLLA-MS biodistributions
into 3D 166Ho activity distributions, radiation-absorbed dose
distributions were estimated by convolution. The results were
validated qualitatively and quantitatively by CT, SPECT, autora-
diography, and dose calibrator measurements.Methods and Materials
Phantom preparation
An ellipse-shaped Perspex phantom (short axis Z 19 cm; long
axis Z 30 cm; height Z 7 cm; volume w3 L) was filled with
agarose gel and 10 cone-hemisphere-shaped (w2  2.5  2.5 cm,
w7 mL) tumor-simulating gel samples. Agarose gel (2%) was
doped with 28 mg/mL MnCl2$4H2O to mimic the T1 relaxation
properties of liver tissue (gel density Z 0.99 g/cm3). Small
amounts of radioactive 166Ho-PLLA-MS were administered to the
liquid gel in a mold. Ho-PLLA-MS (17% by mass holmium,
diameter [mean  SD]Z 30  5 mm) were prepared under good
manufacturing practice as previously described (16). The specific
activity (SA) of
166Ho-PLLA-MS, after activation by thermal
neutron bombardment for 2 hours (6, 17), was determined to be
5.83 MBq/mg using a dose calibrator (VDC-404, Veenstra
Instrumenten B.V., Joure, The Netherlands), which was calibrated
by the Dutch measurement institute (NMI, Delft, The
Netherlands) according to NEN-EN-ISO/IEC 17055:2005 criteria.
Using the same dose calibrator, the activity in each single “tumor”
was determined. A total activity of 152 MBq in 26 mg of 166Ho-
PLLA-MS was distributed over eight “tumors” with the following
amounts: 1.16, 1.16, 2.28, 2.86, 3.52, 3.95, 5.04, and 6.16 mg. As
a control, two “tumors” without microspheres were made. The
used amounts provided a realistic concentration range, in the
knowledge that in clinical practice amounts of 60 mg (scout dose)
to 600 mg (treatment dose) are infused into an average liver
volume of 1.5 l (9), and in the expectation that tumor-to-normal
tissue ratios vary between 2 and 8 (5, 10).Ex vivo liver preparation
To investigate the feasibility of MRI-based radiation-absorbed
dose estimation in a more realistic situation, an ex vivo tumor-
bearing human liver (2.4 kg) was prepared. A total amount of
606.5 mg 166Ho-PLLA-MS (17% by mass) with an activity of 418
MBq (SA Z 0.689 MBq/mg) was prepared to be infused in the
hepatic artery of the liver after excision. Before infusion, the liver
was submersed in purified water doped with 28 mg/mL MnCl2
H2O to mimic the T1 relaxation properties of liver tissue. The total
administered amount of radioactivity was determined retrospec-
tively by subtracting the activity left in the vial, syringe, tubes, and
cloths, as determined using the dose calibrator.
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The MR imaging experiments were performed on a clinical 3T
MR scanner (Achieva, Philips Healthcare, The Netherlands). A
quantitative MR imaging technique was applied, recently devel-
oped to perform T2* relaxometry of Ho-PLLA-MS (15), which is
based on multiple gradient echo sampling of the free induction
decay. For the phantom experiments, the imaging parameters
were as follows: field of viewZ 384 312 mm; flip angleZ 45;
TR/TE1/DTE Z 400/1.11/0.68 ms with 16 echoes; isotropic
voxel size 3 mm; 22 slices; slice gap Z 0 mm, and total acqui-
sition time Z 22.8 s. For the ex vivo liver experiment, similar
parameter settings were used, however, with in-phase/out-of-
phase gradient echo times (TE1/DTE Z 1.15/1.15 ms) to
prevent the influence of waterefat resonance frequency shifts,
and with a slice thickness of 7 mm to increase coverage, resulting
in a voxel size of 3  3  7 mm.CT imaging
The x-ray CT experiments were performed on a 64-slice clinical
CT scanner (Brilliance, Philips Healthcare) for qualitative
comparison of the estimated MRI-based biodistribution and
absorbed dose maps (12). The imaging parameters were as
follows: field of view Z 257  257 mm; matrix Z 512  512;
pixel spacing Z 0.50 mm; collimation Z 64  0.625 mm; pitch
Z 0.5; slice thickness Z 1 mm; slice spacing Z 0.5 mm; x-ray
tube voltage and current 140 kVp and 337 mA, respectively. A soft
tissue reconstruction filter was used.SPECT imaging
Before SPECT, the liver was embedded in a carboxylmethyl
cellulose solution (2.5%) containing four 166HoCl3 markers as
references, and was kept at 20C for 24 hours. SPECT was
acquired using a dual-headed gamma camera equipped with
medium-energy general purpose collimators (Vertex MCD, Phi-
lips Healthcare). Scanning line sources containing 5.5 GBq 153Gd
were used for attenuation correction (energy window: 100 keV 
10%). The 166Ho photo peak window was set to 81 keV  7.5%.
A window centered at 118 keV  6% was used to obtain an
estimate for the down-scatter in both the emission and trans-
mission windows. The 360 SPECT study consisted of 120
projections of 30 s/angle. The imaging parameters were as
follows: acquired matrix size Z 128  128, reconstructed matrix
size Z 128  128  128, isotropic voxel size Z 4.72 mm. A
quantitative iterative reconstruction protocol as previously
described by de Wit et al. was applied (11). To obtain optimal
image resolution, 40 iterations were used. No postreconstruction
filter was applied.Fig. 1. Flowchart indicating the sequence of steps taken to
derive three-dimensional voxel-based 166Ho radiation-absorbed
dose distributions from magnetic resonance imaging (MRI) data.
Ho-PLLA-MS Z 166Ho-loaded poly (L-lactic acid) microsphere.Autoradiography
The frozen carboxylmethyl cellulose-embedded liver was cut into
6-mm-thick slices. The slices were placed on a storage phosphor
screen (8 min exposure time/slice) and scanned using a Storm
imaging system (GE Healthcare Life Sciences, Diegem, Belgium;
200 mm pixel size).Data analysis
MR images
The effective transverse relaxation rate (R2*) was determined
voxelwise using a least-squares fitting algorithm, assuming
monoexponential signal decay (15). The Ho-PLLA-MS concen-
tration distributions ([Ho-PLLA-MS]) were determined based on
the R2* maps and the linear r2* relaxivity of Ho-PLLA-MS, which
represents the change in R2* (DR2*) as a function of the Ho-
PLLA-MS concentration ([Ho-PLLA-MS] Z DR2*/r2*) as
previously described by Seevinck et al. (15) and summarized in
Fig. 1. For Ho-PLLA-MS (17% by mass) at 3T, the relaxivity r2*
was determined to be 180 s1 mg1 mL (15). The concentration
maps of the ex vivo liver were upsampled to a slice thickness of 3
mm using a linear interpolation scheme, leaving the total amount
of Ho-PLLA-MS unaffected. This resulted in 3-mm cubic voxel
sizes for all data. Multiplication of the concentration maps by the
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in each voxel (in milligrams). Then, multiplication by the specific
activity (in MBq/mg) of the administered microspheres at the
moment of infusion provided maps of the activity per voxel (in
MBq/voxel).
SPECT images
The SPECT reconstructions provided an absolute quantitative 3D
activity distribution in Mbq/voxel after multiplication with
a previously determined calibration factor specific for 166Ho (11).
The SPECT reconstructions were upsampled using a linear
interpolation scheme to an isotropic voxel size of 3 mm. To obtain
the amount of Ho-PLLA-MS in milligrams per voxel, the 3D
activity distribution was divided by the specific activity.
Radiation-absorbed dose calculations
A 166Ho dose point-kernel (PK) was calculated using the Monte
Carlo N-Particle transport code (MCNP5; vs. 1.20; LANL, Los
Alamos, NM) according to the method described in Medical
Internal Radiation Dose (MIRD) Pamphlet 17 (18), assuming
a tissue density for liver tissue of 1.06 g/cm3, according to
International Commission on Radiation Units and Measurements
Report 44 (19). Default particle physics settings for MCNP were
used (energy cutoff 1 keV, photoelectric effect, and coherent
photon scattering turned on, Brehmsstrahlung and x-ray
production by electrons). The particle transport of the low-
energy conversion and Auger electrons was not calculated
because the range of these particles in liver tissue is well below
the 3-mm voxel size; the total electron energy (27 keV/decay)
was considered to be locally deposited in each source voxel. The
3D point-symmetric dose PK was generated on a 29  29  29
matrix, with the source located in the center, providing the
absorbed energy in 3-mm cubic voxels per decay for the emis-
sion spectrum of 166Ho as a function of the source-to-target
voxel center-to-center distance (Fig. 2). Radiation-absorbed
dose distributions were estimated by convolving the MRI- and
SPECT-based activity distributions with the 166Ho dose kernel,
after converting absorbed energies to dose per activity by takingFig. 2. The absorbed energy in 3-mm cubic voxels in liver
tissue per decay for the emission spectrum of 166Ho as a function
of the distance between source and target voxel centers.into account the 166Ho decay constant and voxel mass and
assuming complete trapping of activity.
Volume of interest analysis
The total amount of Ho-PLLA-MS in the gel phantom was
determined for each “tumor” separately by a volume of interest
(VOI) analysis on R2* maps and SPECT reconstructions.
Cylinder-shaped VOIs were manually drawn around each “tumor,”
taking into account a 5-mm margin to ensure that the entire
“tumor” was included. Summation of the included amount of Ho-
PLLA-MS in milligrams per voxel provided the total amount of
Ho-PLLA-MS in milligrams for each “tumor” for both imaging
modalities, which also reflects the total activity per “tumor” when
dividing by SA.
The excised liver was manually segmented on T2*-weighted
MR images to enable a VOI analysis of the whole liver. For
analysis of the SPECT data, a VOI was defined by segmenting the
liver on three orthogonal projections of the 3D activity maps. The
estimated total amount and activity of 166Ho-PLLA-MS were
compared with the values obtained with the dose calibrator.
Maximum-intensity projections and summed-intensity projections
(SIPs) were calculated for qualitative comparison. For quantitative
analysis using a cumulative doseevolume histogram, the admin-
istered activity was extrapolated to that for a uniform average liver
dose of 40 Gy. For a 2.4-kg liver, 6.0 GBq of 166Ho activity is
required to deliver 40 Gy (9), which is simulated by multiplying
the net activity administered to the liver (368 MBq) by a factor of
16.3 (368 MBq  16.3Z 6.0 GBq). Finally, a single slice analysis
was performed by comparing estimated MRI-based absorbed dose
maps with CT and SPECT-based absorbed dose maps with
autoradiography.Results
In vitro experiments
The absorbed energy in liver tissue per decay for the emission
spectrum of 166Ho as a function of the distance between source
and the center of a 3-mm cubic target voxel were generated by
MCNP and from MIRD Pamphlet 17 (Fig. 2) and were subse-
quently used to construct a 166Ho dose PK. Good agreement was
observed both visually and quantitatively between MRI-based
and SPECT-based radiation-absorbed dose maps (Fig. 3). The
MRI-based dose distributions clearly reflected the actual cone-
hemisphere shape of the tumor-simulating gel samples contain-
ing 166Ho-PLLA-MS; however, the SPECT-based dose maps
depicted smoothed and sphere-shaped dose distributions. These
differences are related to the inherently low resolution of SPECT
and the subsequent upsampling (4.72 mm to 3 mm) necessary to
match the cubic voxel size of the dose PK, leading to increased
partial volume effects and spatial blurring at the edges of the
“tumor.” In the center of the “tumors,” where partial volume
effects have less influence, both modalities presented similar
absorbed dose values, with maximal values of 65 Gy. In some
areas outside the “tumors,” where no activity was present based
on prior knowledge, nonzero values were found. These offsets in
absorbed dose directly related to macroscopic magnetic field
inhomogeneities induced by sharp edges in the Perspex
phantom, which locally increased the R2* value and thereby
falsely indicated the presence of 166Ho-PLLA-MS, as was also
Fig. 3. Estimated magnetic resonance imaging (MRI)-based (a) and single photon emission computed tomography (SPECT)-based
radiation-absorbed dose distributions in Gy (b), depicting the tumor-simulating gel samples in four consecutive slices (isotropic voxel size
Z 3 mm) of the agarose gel phantom.
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presented in Fig. 4a.
The VOI analysis of the tumor-simulating gel samples revealed
good agreement between the total amounts per “tumor” of
Ho-PLLA-MS as determined by MRI and by both SPECT and
the dose calibrator (Fig. 4). This was demonstrated by linear
regression analysis, relating SPECT- and MRI-based total amount
and activity of 166Ho-PLLA-MS per “tumor” to the values
obtained with the dose calibrator, revealing a slope of 1.00 with
R2 Z 0.99 for SPECT data, and a slope of 1.05 with R2 Z 0.99
for MRI data.Fig. 4. Total estimated amounts of 166Ho-loaded poly (L-lactic ac
responance imaging (MRI) (a) and with single photon emission compute
166Ho-loaded poly (L-lactic acid) microsphere as determined with a d
demonstrated (c).Ex vivo liver
Analysis of the MRI data provided a total amount of 521 mg of
Ho-PLLA-MS in the ex vivo liver, containing a total activity of
359 MBq. This agrees well (2.4%) with the values found by the
dose calibrator (534 mg containing 368 MBq). SPECT over-
estimated the dose calibrator measurements by 7.9% (576 mg
containing 397 MBq). Cumulative doseevolume histograms
obtained from MRI- and SPECT-based absorbed dose estimations
in the liver showed a high degree of resemblance (Fig. 5f). This
was visually supported by the maximum-intensity projectionsid) microsphere in the “tumors” as determined with magnetic
d tomography (SPECT) (b), plotted against the known amounts of
ose calibrator. The correlation between MRI and SPECT is also
Fig. 5. Magnetic resonance imaging (MRI)-based and single photon emission computed tomography (SPECT)-based dose distributions
in the ex vivo liver. Maximim-intensity projections (a, d) and summed-intensity projections (SIPs) (b, e) of the three-dimensional dose
distribution estimated from MRI (a, b) and SPECT data (d, e) show excellent agreement, as is also reflected by the MRI-based and SPECT-
based cumulative doseevolume histograms (f). The CT SIP image (c) shows excellent agreement with the biodistribution of 166Ho-loaded
poly (L-lactic acid) microsphere depicted in the MRI SIP (b). Scale bars in a, b, d, and e are in Grays.
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based dose maps, respectively, which depict similar dose distri-
butions macroscopically. The CT SIP image (Fig. 5c) shows
excellent visual agreement with the biodistribution of Ho-PLLA-
MS as depicted in the MRI SIP, both having been obtained from
the same experimental setup, which prevented translation, rota-
tion, and deformation.
Figure 6aec shows a T2*-weighted MR image of the liver, the
accompanying MRI-based absorbed dose distribution, and a CT
image of the same slice, in which Ho-PLLA-MS is depicted
hyperintense (12). Excellent visual agreement can be observed
between the hypointensities in the T2*-weighted image, the high
values in the absorbed dose map, and the hyperintensities in the
CT image. Although macroscopically and quantitatively MRI- and
SPECT-based dose maps (Fig. 6b and e) show similar absorbed
dose distributions, clear differences can be observed as well. Apart
from differences related to acquisition voxel size, differences
related to translation and rotation can be attributed to the fact that
before SPECT, the liver was transferred into a setup with radio-
active markers used as landmarks to enable comparison of SPECT
and autoradiographic imaging. These autoradiographs showed
a high degree of visual resemblance with the SPECT-based
absorbed dose distributions (Fig. 6f). However, as may be
expected, the SPECT reconstruction and dose map depict lower
resolution and smoothed distributions compared with the
autoradiograph.Discussion
This study demonstrates that quantitative MRI enables accurate
estimation of the 166Ho-PLLA-MS activity distribution in vitro
and in ex vivo human tumor-bearing liver in a scan duration equal
to a single breath-hold. Furthermore, it was shown that by
convolution of a 3D MRI-based activity distribution with a 166Ho
dose PK, it is possible to estimate the radiation-absorbed dose
distribution. These results, in combination with the fact that MRI
provides high resolution and excellent soft tissue contrast, has
relatively short acquisition times, and allows real-time monitoring
during microsphere delivery to the tumor site (13, 14), suggest that
MRI is an attractive modality to perform treatment planning and
follow-up of transcatheter RE of hepatic malignancies with 166Ho-
PLLA-MS in a clinical setting. Interestingly, the sensitivity of
MRI for Ho-PLLA-MS is independent of radioactivity, enabling
intraprocedural biodistribution assessment and dose prediction
using “cold” Ho-PLLA-MS and the acquisition of follow-up scans
after treatment long after 166Ho has decayed.
The accuracy of MRI-based absorbed dose estimations of
166Ho-PLLA-MS is directly related to the accuracy of the Ho-
PLLA-MS biodistribution assessment. In this regard, two limita-
tions should be addressed. First, the MRI-based approach provides
a single concentration value for each volume element, assuming
an average activity in the entire voxel. This will not be the case in
Fig. 6. Single slice qualitative comparison of the biodistribution, activity distribution, and estimated radiation-absorbed dose distribution
obtained with magnetic resonance imaging (MRI), computed tomography (CT), single photon emission CT (SPECT), and autoradiography.
The T2* weighted image (a) and accompanying MRI-based dose map (b) show similar distributions to the CT image (c). The single slice
MRI and SPECT-based dose maps (b and e) macroscopically and quantitatively agree well, taking into account object rotation. The SPECT
image (d) (4.7-mm slice thickness) and the accompanying estimated SPECT dose map (3-mm slice thickness) show a high degree of visual
resemblance to the autoradiograph (f) (6-mm slice thickness). Four markers are shown as a reference. Scale bars in b and e are in Grays.
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provides a highly inhomogeneous particle distribution at the level
of the microvasculature. When a dose PK is applied for absorbed
dose estimation in such a case, a homogeneous tissue composition
and uniform radionuclide distribution within voxels is implicitly
but falsely assumed, which may be expected to affect the accuracy
of the dose PK convolution method. These well-known charac-
teristics of voxel dosimetry have already been addressed by Bolch
et al. (18). Second, the accuracy of the MRI-based biodistribution
assessment is limited by local variations of baseline R2* values in
the liver, inasmuch as these variations complicate accurate
determination of the increase of the R2* value (DR2*) attributed to
the presence of Ho-PLLA-MS. It is important to be aware of this
limitation; however, it should also be realized that its maximum
influence can easily be predicted and therefore taken into account
in the treatment optimization (e.g., an erroneous increase of R2*
by 10 s1 translates to a local concentration increase of 0.05 mg/
mL (Z DR2*/r2*)).
When higher accuracy and consistency are needed, for
example for pretreatment intrahepatic dose prediction, both the
baseline R2* map and the postadministration R2* map could be
acquired in the same scan session. This would ensure intrinsic
image registration and enable voxelwise subtraction of spatially
varying baseline R2* values, leading to potentially very accurateDR2* maps and activity maps because tissue variability can be
overcome. In practice, this will require MRI-guided catheteriza-
tion and administration of 166Ho-PLLA-MS. Our group has
previously demonstrated the feasibility of this method in pigs (14);
however, the current absence of MR-compatible and visible
guidewires and catheters approved for clinical use is an important
limiting factor. Recent developments in this field are promising
and may be expected to enable fully MRI-guided catheter-directed
RE (20). Such an MRI-guided approach will be particularly useful
for patient-specific localized treatment, as is provided in radiation
segmentectomy (3) (in which RE is selectively performed in only
one or two predefined hepatic segments), which may be expected
to increase the safety and efficacy of RE (3).
In conclusion, quantitative MRI was demonstrated in this study
to provide accurate 3D 166Ho-PLLA-MS activity distributions at
the voxel level, facilitating localized intrahepatic radiation-
absorbed dose estimation by convolution with a 166Ho dose PK
to enable RE treatment planning optimization and evaluation.
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